Company / Cost of Revenue
Adaptive Biotechnologies Corp Cost of Revenue History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$71.4M
FY2025
5-year range
$49.3M / $75.6M
FY2021-FY2025
Trend
-1.0%
vs FY2024
Sector context
#51 of 85
Health Care
What the data says
At $71M, Adaptive Biotechnologies Corp's cost of revenue ranks #35 of 85 in the Health Care sector. Improved from $76M to $71M over the past 2 years.
Based on SEC 10-K filings.
$71M in FY2025 with a 5-year CAGR of +25.9%.
Improved from $76M to $71M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +7.2%
- 5-Year CAGR
- +25.9%
- 10-Year CAGR
- -
Sector benchmark
#35 of 85 in Health CareTop 40% of 85This company $71.4M Sector average $2.0B
▼
-96.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.9%, indicating consistent growth.
- In FY2025, cost of revenue decreased 1.0% year-over-year.
- Ranks #51 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.45 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $71.4M | -1.0% |
| FY2024 | $72.1M | -4.6% |
| FY2023 | $75.6M | +30.5% |
| FY2022 | $57.9M | +17.5% |
| FY2021 | $49.3M | +118.8% |
| FY2020 | $22.5M | +1.1% |
| FY2019 | $22.3M | +13.2% |
| FY2018 | $19.7M | +25.4% |
| FY2017 | $15.7M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026